Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
24 sept. 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors
17 sept. 2024 08h00 HE
|
ImmuneSensor Therapeutics
Composition and methods patent granted claims covering compounds for treating broad range of inflammatory and autoimmune diseases and built on foundational intellectual property for the discovery of...
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
01 mai 2024 08h00 HE
|
ImmuneSensor Therapeutics
DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the...
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
01 mai 2024 07h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer.
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
05 janv. 2024 16h01 HE
|
Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
Immunology Collaboration and Licensing Agreements Analysis Report 2023
17 nov. 2023 06h13 HE
|
Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
Cyrex Announces Innovative New Immunophenotyping Test Panel, The Lymphocyte MAP™
21 juil. 2021 09h00 HE
|
Cyrex Laboratories
PHOENIX, July 21, 2021 (GLOBE NEWSWIRE) -- Cyrex Laboratories, a clinical laboratory specializing in functional immunology and autoimmunity, today announced The Lymphocyte MAP™, which is the result...
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease
02 juin 2021 07h00 HE
|
Nurix Therapeutics, Inc.
Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European Alliance of Associations for Rheumatology (EULAR)...
Beyond Celiac Awards Nearly $450,000 in Research Grants for Groundbreaking Studies on Celiac Disease
16 août 2019 08h51 HE
|
Beyond Celiac
Philadelphia, PA, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Beyond Celiac, the leading research-driven celiac disease organization working to drive diagnosis, advance research and accelerate the discovery...
Last Chance to Register: Beyond Celiac Global Webinar
04 oct. 2018 14h53 HE
|
Beyond Celiac
Philadelphia, PA, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Thousands have registered for the upcoming live webcast of the Second Annual Beyond Celiac Global Research Symposium. Others who are interested...